FDA clears first generic versions of Fosamax

02/6/2008 | U.S. News & World Report

Both Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals have obtained FDA approval for their generic versions of Fosamax, Merck & Co.'s osteoporosis drug. Barr got regulatory clearance to produce a 70-mg dose of the drug, while Teva's application was for 5-mg, 10-mg, 35-mg, 40-mg and 70-mg versions of the treatment.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA